目的 觀察丹黃祛瘀膠囊聯(lián)合克林霉素治療慢性盆腔炎的臨床療效。方法 選取2015年1月-2016年1月上海市第一人民醫(yī)院寶山分院進行治療的慢性盆腔炎患者160例，隨機分為對照組和治療組，每組各80例。對照組患者口服鹽酸克林霉素棕櫚酸酯顆粒，2包/次，2次/d。治療組患者在對照組的基礎(chǔ)上口服丹黃祛瘀膠囊，4粒/次，3次/d。兩組患者均連續(xù)治療4周。治療后，評價兩組患者的臨床療效，同時比較治療前后兩組患者的炎癥因子水平、平均包塊直徑以及不良反應。結(jié)果 治療后，對照組和治療組的總有效率分別為81.25%、92.50%，兩組總有效率比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組患者的炎癥因子水平均較治療前顯著降低，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；且治療組患者的炎癥因子水平顯著優(yōu)于對照組患者，兩組比較差異具有統(tǒng)計學意義（P<0.05）。兩組患者平均包塊直徑均較治療前顯著縮小，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；且治療組治療后平均包塊直徑小于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療組的不良反應發(fā)生率為12.50%，顯著低于對照組患者的27.50%，兩組不良反應發(fā)生率比較差異有統(tǒng)計學意義（P<0.05）。結(jié)論 丹黃祛瘀膠囊聯(lián)合克林霉素治療慢性盆腔炎的臨床效果較好，可顯著改善炎癥因子水平和平均包塊直徑，且安全性較好，具有一定的臨床推廣應用價值。

Objective To observe the clinical efficacy of Danhuang Quyu Capsule combined with clindamycin in treatment of chronic pelvic inflammatory. Methods Patients (160 cases) with chronic pelvic inflammatory in Baoshan Branch of Shanghai First People's Hospital from January 2015 to January 2016 were randomly divided into control and treatment groups, and each group had 80 cases. Patients in the control group were po administered with Clindamycin Palmitate Hydrochloride Flavored Granules, 2 bags/time, twice daily. Patients in the treatment group were po administered with Danhuang Quyu Capsule on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and inflammatory factors level, mean mass diameter, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.25% and 92.50%, respectively, and there was difference between two groups (P < 0.05). After treatment, the inflammatory factors in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the inflammatory factors in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). The mean mass diameter in two groups was significantly reduced, and the difference was statistically significant in the same group (P < 0.05). And the mean mass diameter in the treatment group was significantly less than those in the control group, with significant difference between two groups (P < 0.05). The incidence of adverse reactions in the treatment group was 12.50%, which was significantly lower than 27.50% in the control group and there were differences between two groups (P < 0.05). Conclusion Danhuang Quyu Capsule combined with clindamycin has significant clinical efficacy in treatment of chronic pelvic inflammation, and can improve inflammatory factors level and mean mass diameter with good safety, which has a certain clinical application value.